Please login to the form below

Not currently logged in
Email:
Password:

Depomed and Watson sign co-promotion deal

Depomed and Watson Pharmaceuticals have entered into a co-promotion agreement for ProQuin XR, Depomed's extended-release formulation of ciprofloxacin for the treatment of uncomplicated urinary tract infections.

Depomed and Watson Pharmaceuticals have entered into a co-promotion agreement for ProQuin XR, Depomed's extended-release formulation of ciprofloxacin for the treatment of uncomplicated urinary tract infections.

Under the agreement, Depomed has granted Watson a co-exclusive right to promote ProQuin XR for the urology and long-term care specialties in the US and its possessions, including Puerto Rico.

Per the agreement, Depomed will book top-line revenue and Watson will receive a portion of the profits. Watson and Depomed plan to re-launch ProQuin XR in the US urology market by the end of this year.

Depomed retains manufacturing and distribution rights and Watson will be responsible for promotion to physicians in urology and long-term care.

Extended release versions of ciprofloxacin are also sold by Germany-based Bayer and Indian pharmaceutical company Ranbaxy.

According to a Market Research report, fluoroquinolone sales are expected to remain relatively constant to 2011. The fluoroquinolone market is heavily dominated by ciprofloxacin and levofloxacin, which together command 65 per cent (USD 3.3bn) of global sales.

25th July 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Virgo Health

Virgo Health is an award-winning global healthcare communications and medical education agency. We dispense pioneering and creative campaigns, driven by...

Latest intelligence

INFOGRAPHIC 02: The Importance of clinical study websites
Here’s a infographic of why clinical study websites are important to patient recruitment and retention strategies…...
Working with, Advocating for, and Empowering Patients
A holistic view of how to work with patients virtually...
The concordance conundrum: the value of improving patient experience
This is the first in a series of articles where we explore how the current climate presents companies with a multitude of opportunities to improve communication between healthcare organisations and...

Infographics